Correlation between KIR2DL5B and treatment outcomes in patients treated with imatinib and nilotinib in the TIDEL-II study.KIR2DL5B^POS patients have inferior achievement of molecular responses: (A) cumulative incidence of MMR and (B) MR^4.5. KIR2DL5B^POS patients also have inferior TFS and EFS compared with KIR2DL5B^NEG patients. (C) TFS events include transformation to accelerated phase and blast crisis, as well as death from any cause. (D) EFS events include TFS events and loss of MMR or BCR-ABL1 increasing to a level >1% from a nadir ≤1%, kinase domain mutations, and discontinuation of TIDEL-II treatment (imatinib and/or nilotinib) for any cause. The difference in overall survival as segregated by KIR2DL5B status is not statistically significant (data not shown).